The European Patients’ Academy on Therapeutic Innovation

Jan GeisslerEUPATI Director, Germany

Window of opportunity in accelerating medicines R&D

Great challenges ahead: Personalized medicine, translational medicine, increasing development cost, pressure on healthcare budgets

The regulatory and innovation environment is ready to involve patients to effectively meet unmet needs

Patients…• seek up-to-date, credible, understandable information

about innovation in treatments• are largely unaware about clinical trials, translational

research, personalized medicine, pharmacoeconomics, their key role

Patient advocates…• like to advise on protocol design, informed consent,

ethical review, marketing authorization, value assessment, health policy

• lack the education and training required to participate as a partner in drug research and development

FP7-funded PatientPartner project demonstrateda clear need & willingness to contribute

Unmet need of patient & public, great willingness to contribute!

Launched Feb 2012, runs for 5 years,29 consortium members,IMI-funded

will develop and disseminateobjective, credible, correct and up-to-date public knowledge about medicinesR&D

A paradigm shift in empoweringpatients on medicines R&D

IMI-funded EUPATI will develop and disseminate accessible, well-structured and

user-friendly information and education on medicines R&D

build competencies among well informed patients and the public about pharmaceutical R&D

build expert capacity in patient advocates

create the leading public library on patient information in seven most common languages under public licensing

establish a widely used, sustainable infrastructure for objective, credible, correct and up-to-date knowledge

facilitate patient involvement in R&D to support industry, academia, authorities and ethics committees

EUPATI: European Patients' Academy on Therapeutic Innovation

Led by pan-EU patient umbrella organisations

Strong impetus from key academic partners and non-profit organisations

Key industry expertise in medicines R&D

Strong Consortium

Advisory bodies committed to ensure independence, transparency, good governance• EMA, Swissmedic, MHRA, BfArM• Key experts in bioethics, genetics, HTA,

economics, evidence based med, patient advocacy

• Ethics Panel Ethical Framework, Code of Conduct:

• Ground rules for anonymity, confidentiality, informed consent, social research, ethical review, professional integrity, publication ethics, transparency, independence and trust.

Ensuring Objectivity, Transparencyand Independence are vital

EUPATI platform fully loaded with training, education, information material in multiple languages

EUPATI Patient Ambassador, Patient Journalist, Train-the-Trainer Programme in place

Good practice guideline for patient involvement released

Annual Conferences and at least 5 Regional Workshops performed. Expert network established.

EUPATI in 2016: What we will have achieved

Get to know us!

Web:www.patientsacademy.eu

Twitter: @eupatientsas well as: